Efficacy and safety of biological treatment in Crohn’s disease: our experience

Domżał-Magrowska, Danuta; Talar-Wojnarowska, Renata; Kotynia, Justyna; Durko, Łukasz; Małecka‐Panas, Ewa

doi:10.5114/pg.2011.25379

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biological treatment represents a significant advance in the treatment of CD patients. These drugs reduce the number of surgical interventions and lead to endoscopic remission of the disease [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Efficiency and safety of one-year anti-TNF-α treatment in Crohn’s disease: a Polish single-centre experience

Sochal¹,

Krzywdzińska²,

Gabryelska³

et al. 2020

Self Cite

View full text Add to dashboard Cite

Introduction: Anti-TNF-α therapy of Crohn's disease (CD) represents considerable progress in inflammatory bowel disease (IBD) treatment; however, many patients still require surgical intervention. The Polish National Insurance Fund currently only covers up to 2 years of infliximab (IFX) therapy in CD patients and 1 year of adalimumab (ADA). Aim: To estimate the effectiveness and side effects of the anti-TNF-α Polish therapeutic program in CD patients. Material and methods: In this retrospective study, medical documentation of 80 CD patients treated with anti-TNF-α (IFX or ADA) was analysed. Fifty-two patients finished 1 year of therapy, and 28 individuals did not complete it due to lack of response to treatment or severe side effects. Results: After treatment, 27 (67.50%) patients achieved a semi-annual remission and 14 (35%) achieved yearly remission. Twenty percent of patients experienced severe side effects such as anaphylactic shock, pneumonia, shingles, or upper respiratory tract infections. A strong negative correlation between the number of patients in remission and the period since therapy termination (r =-0.996, p < 0.001) was found. During the 1-year follow-up, 20 patients were re-enrolled in the biological therapy program (the median time to next therapy was 231 days IQR: 126.5-300.5) Conclusions: Anti-TNF-α treatment in CD is relatively safe. The restricted time period of the therapy affects the clinical course of the disease and entails the need to resume biological therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficiency and safety of one-year anti-TNF-α treatment in Crohn’s disease: a Polish single-centre experience

Sochal¹,

Krzywdzińska²,

Gabryelska³

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Tumour necrosis factor α is a cytokine that takes an important role in the pathogenesis of CD. Biological therapies increased the number of achieved remissions, allowed for long-term maintenance and reduced symptoms during follow-up [ 11 ]. Anti-TNF-α introduced in order to obtain remission of CD may induce de novo psoriasis or exacerbate existing skin lesions.…”

mentioning

confidence: 99%

Extraintestinal manifestations of Crohn’s disease

Wójcik¹,

Loga²,

Włodarczyk³

et al. 2016

View full text Add to dashboard Cite

Efficacy and safety of biological treatment in Crohn’s disease: our experience

Cited by 2 publications

References 16 publications

Efficiency and safety of one-year anti-TNF-α treatment in Crohn’s disease: a Polish single-centre experience

Efficiency and safety of one-year anti-TNF-α treatment in Crohn’s disease: a Polish single-centre experience

Extraintestinal manifestations of Crohn’s disease

Contact Info

Product

Resources

About